- Home
- JBGS vs ORIC Comparison
JBGS vs ORIC Comparison
Compare JBGS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | ORIC |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | 104 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.3M | 861.3M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JBGS | ORIC |
|---|---|---|
| Price | $14.43 | $8.31 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $15.00 | ★ $19.73 |
| AVG Volume (30 Days) | 563.4K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $498,598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.99 | $5.51 |
| 52 Week High | $24.30 | $14.93 |
Technical Indicators
Market Signals| Indicator | JBGS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 37.06 |
| Support Level | $14.17 | $7.90 |
| Resistance Level | $16.07 | $11.22 |
| Average True Range (ATR) | 0.49 | 0.44 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 22.02 | 30.75 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.